BioCryst to Release First Quarter Financial Results on April 25, 2001

Apr 19, 2001, 01:00 ET from BioCryst Pharmaceuticals, Inc.

    BIRMINGHAM, Ala., April 19 /PRNewswire/ --
 BioCryst Pharmaceuticals, Inc. (Nasdaq:   BCRX) today announced the Company will
 release its financial results for the first quarter 2001, before the Nasdaq
 market opens on Wednesday, April 25, 2001.
     The Company will conduct a conference call, which is open to the public,
 at 10:00 am EDT on Wednesday, April 25.  The conference call dial-in number is
 1-800-289-0496, and the passcode number is 440430.  The conference call will
 also be available by webcast on the Company's investor relations website,
 www.biocryst.com .
     For those unable to listen at the designated time, a conference call
 replay will be available for two days following the conference call, from
 approximately 1:00 p.m EDT on Wednesday, April 25 to midnight on Friday,
 April 27, 2001.  The conference call replay can be heard by dialing
 1-888-203-1112 and entering passcode number 440430.  The webcast will also
 remain available for replay over BioCryst's website until June 30, 2001.
     Founded in 1986, BioCryst Pharmaceuticals, Inc. is a biopharmaceutical
 company focused on the development of pharmaceuticals for the treatment of
 antiviral, inflammatory/autoimmune and cardiovascular diseases and disorders.
 BioCryst's most advanced drug candidate, RWJ-270201 (formerly known as
 BCX-1812), is a neuraminidase inhibitor designed to treat and prevent viral
 influenza.  The Company licensed this drug candidate to The R.W. Johnson
 Pharmaceutical Research Institute and Ortho-McNeil Pharmaceutical, Inc., both
 Johnson & Johnson companies.
 
 

SOURCE BioCryst Pharmaceuticals, Inc.
    BIRMINGHAM, Ala., April 19 /PRNewswire/ --
 BioCryst Pharmaceuticals, Inc. (Nasdaq:   BCRX) today announced the Company will
 release its financial results for the first quarter 2001, before the Nasdaq
 market opens on Wednesday, April 25, 2001.
     The Company will conduct a conference call, which is open to the public,
 at 10:00 am EDT on Wednesday, April 25.  The conference call dial-in number is
 1-800-289-0496, and the passcode number is 440430.  The conference call will
 also be available by webcast on the Company's investor relations website,
 www.biocryst.com .
     For those unable to listen at the designated time, a conference call
 replay will be available for two days following the conference call, from
 approximately 1:00 p.m EDT on Wednesday, April 25 to midnight on Friday,
 April 27, 2001.  The conference call replay can be heard by dialing
 1-888-203-1112 and entering passcode number 440430.  The webcast will also
 remain available for replay over BioCryst's website until June 30, 2001.
     Founded in 1986, BioCryst Pharmaceuticals, Inc. is a biopharmaceutical
 company focused on the development of pharmaceuticals for the treatment of
 antiviral, inflammatory/autoimmune and cardiovascular diseases and disorders.
 BioCryst's most advanced drug candidate, RWJ-270201 (formerly known as
 BCX-1812), is a neuraminidase inhibitor designed to treat and prevent viral
 influenza.  The Company licensed this drug candidate to The R.W. Johnson
 Pharmaceutical Research Institute and Ortho-McNeil Pharmaceutical, Inc., both
 Johnson & Johnson companies.
 
 SOURCE  BioCryst Pharmaceuticals, Inc.